StockMarketWire.com - Immunodiagnostics group Oncimmune Holdings said it had recorded positive results from a study in Scotland of its early lung-cancer detection technology.

The study recruited 12,210 patients, each of whom were followed up for a minimum of two years.

'The company is pleased to report that the study met its primary endpoint showing that the use of EarlyCDT-Lung with subsequent X-ray and computerised tomography scan reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice,' the company said.

A submission of the full study findings was being prepared for a leading peer-reviewed medical publication and was expected to be published in the third quarter.

At 9:01am: [LON:ONC] Oncimmune Holdings Plc share price was +7.5p at 100p



Story provided by StockMarketWire.com